ABSTRACT
Objective To investigate the reliable methods for establishing models of acute radiation enteritis (ARE) and the criteria used to judge whether the model is successfully established.Methods A total of 98 rats were randomly divided into normal control group (group A),fractionated dose group B (4 Gy/fraction for 3 fractions),fractionated dose group C (4 Gy/fraction for 4 fractions),fractionated dose group D (4 Gy/fraction for 5 fractions),single fraction group E (12 Gy in a single fraction),single fraction group F (16 Gy in a single fraction),and single fraction group G (20 Gy in a single fraction).Abdominal irradiation was performed for all rats,and the changes in body weight and defecation were observed.Magnetic resonance imaging (MRI) was performed on days 3-5 after irradiation,and on the 4th day,anatomy was performed to measure the length of small intestine with edema,blood samples were collected to measure endotoxins,and the specimens of small intestine were collected to observe pathological changes.The independent-samples t-test was used for comparison between groups.Results After irradiation,groups D,E,F,and G experienced varying degrees of diarrhea and had positive results from endotoxins test.Group D had a longer length of small intestine with edema than group C (P=0.00) and had a similar length as group E (P=0.46).Groups E,F,and G showed dilation and dropsy in the intestinal canal on MRI,and groups F and G showed patchy signals of dropsy in the abdominal cavity.Groups F and G showed varying degrees of necrosis in the small intestine and died within 14 days after irradiation.Conclusions When the radiation dose is 33-46 Gy (biologically equivalent dose),both single dose and fractionated dose can successfully establish the model of ARE,while fractionated dose can be better controlled.
ABSTRACT
Objective: To evaluate the therapeutic effects of Rituximab combined with CHOP on B cell non-Hodgkin's lymphoma. Methods: A prospective study with concurrent control group was carried out. A total of 60 cases of B cell non-Hodgkin's lympoma were divided into 2 groups. The 30 cases in the research group received Rituximab combined with CHOP regimen. The 30 cases in the control group were treated with CHOP regimen alone. CHOP regimen (Cyclophospham 600mg/m~2 IV, Vincristine 1.4mg/m~2 Ⅳ, and Adriamy-cin piarubicin 50mg/m~2 IV) was administered on the first day of chemotherapy course. Prednisone 100mg/m~2 was administered orally from the first day to the fifth day. The cycle was repeated every 21 days and the patients received at least 3-6 cycles of chemotherapy. The therapeutic effect was assessed. Results: The complete remission (CR) rate and total response rate were 66.7% (20/30) and 90.0% (27/30) in the research group and 39.97% (12/30) and 56.7% (17/30) in the control group. The therapeutic differences between the two groups showed a statistical significance (P＜0.05). Conclusion: Compared with CHOP regimen chemotherapy, Rituximab combined with CHOP regimen shows better therapeutic effect. The side effects in the research group are similar to those in the control group. Rituximab combined with CHOP regimen can be the first choice in the treatment for B cell non-Hodgkin's lymphoma.